Market Overview:
Biomarkers are molecules found in biological fluids or tissues that indicate normal or abnormal processes in the body. Biomarkers play an important role in disease prevention, diagnosis, and treatment. They help to detect diseases early, monitor treatment response, and predict disease progression.
Market key trends:
One of the key trends in the biomarkers market is the increasing focus on protein biomarkers. Protein biomarkers are increasingly used in disease diagnostics and drug development. They provide biomarkers of biological processes and pathways that can help understand disease development and progression. For example, protein biomarkers are used in cancer diagnostics to detect the presence of tumor cells and monitor response to treatment. Growth in the biotechnology and pharmaceutical industries is also driving the demand for protein biomarkers in drug discovery and development processes.
Segment Analysis
The global biomarkers market is segmented by type, disease indication, product, application, and end user. Based on type, it is divided into safety biomarkers, efficacy biomarkers, and validation biomarkers. The safety biomarkers segment holds the largest share owing to increasing drug development activities for various chronic diseases.
The Global Biomarkers Market Share is estimated to be valued at US$ 17.97 Mn in 2023 and is expected to exhibit a CAGR of 13. % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Key Takeaways
The global biomarkers market is expected to witness high growth, exhibiting a CAGR of 13% over the forecast period, due to increasing R&D investment in drug development for cancer and other chronic diseases.
Regional analysis: North America holds the largest market share owing to presence of major biomarker companies and growing pharmaceutical R&D in the US. Asia-Pacific is expected to witness highest CAGR during the forecast period due to rise in clinical research outsourcing by Western pharmaceutical companies and increasing healthcare expenditure in China and India.
Key players analysis: Key players operating in the biomarkers market are Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Acobiom, Apis Assay Technologies Ltd., Eagle Biosciences, Inc., Beckman Coulter, Inc., PerkinElmer Inc., Biopanda Reagents Ltd, Quanterix, Secure Diagnostics Pvt. Ltd., BioVision Inc., Merck KGaA, R&D Systems, Life Diagnostics, QuantaMatrix Inc., Nanjing Synthgene Medical Technology Co., Ltd, LifeSpan BioSciences, Inc, Wako USA, BioLegend, Inc, Abnova Corporation, and Abbexa. Acobiom and Apis Assay Technologies are new players in the safety biomarkers segment.
